The firm comments, "Bottom Line: Our due diligence points to a significant transformation occurring in the obesity space, similar in scope to smoking cessation a decade ago. The result should be a robust market expansion story advanced by: 1) novel more potent drugs; 2) increasing reimbursement; 3) significant sales & marketing efforts, and; 4) more approvals of effective therapies with co-morbid disease benefits. The initial Qsymia launch has been slow but significant drivers lie on the horizon."

For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.